KALV Christopher Yea sells $475K worth of shares
Jul 11, 2025, 4:35 AM
0.00%
What does KALV do
KalVista Pharmaceuticals, based in Cambridge, Massachusetts, specializes in small molecule protease inhibitors for unmet medical needs, focusing on hereditary angioedema treatments like sebetralstat and Factor XIIa inhibitors. The company went public in April 2015 and employs 150 staff.
Christopher Yea sold 30,250 shares of KALV on 9 July at $15.69 per share, worth a total of $475K. They now own 127,939 KALV shares, or a 19% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.